Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI

Summary

The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.

Timeline

Start

2000-09

Primary completion

—

Completion

2005-11

Drugs

Indications